Biopharmaceutical Company Announces Positive Interim Results For Non-Hodgkin's Lymphoma

Groundbreaking Phase 1 Results for CASI Pharmaceuticals’ BI-1206 Treatment for Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China.

Major strides are being made in the field of cancer research. One of the key players in this area is CASI Pharmaceuticals, a biopharmaceutical company focused on the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs. Recently, the company announced positive interim results for its ongoing Phase 1 trial of BI-1206.

https://stockregion.app/p/biopharmaceutical-company-announces

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

2641 Views

Comment

Stock Region

112Followers

0Following

253Visitors